ÂÜÀòÂÒÂ×

Alisa Selimovic currently serves as Executive Chair at Resseptor Therapeutics and holds the position of Senior Investment Manager at IP Group plc, where engagement includes roles as Investment Manager focused on Life Sciences. Selimovic is a Board Observer for both RAGE Biotech and Jetra Therapeutics. Previous experience includes Business Development Manager for Medicine at the University of Sydney and Corporate Development Associate at Circassia, where responsibilities involved evaluating M&A and in-licensing opportunities. Additional roles encompassed positions as Senior and Business Analyst at PharmaVentures and research-focused roles at the University of Oxford and SA Pathology. Alisa Selimovic's educational background includes a DPhil in Biomedical/Medical Engineering from the University of Oxford and a Bachelor of Engineering from Flinders University, along with completion of the Company Directors Course at the Australian Institute of Company Directors.